Compass Therapeutics (NasdaqCM:CMPX) 2025 Conference November 20, 2025 07:30 AM ET Company ParticipantsThomas Schuetz - Founder, CEO and Vice Chairman of the BoardMaury Raycroft - Equity ResearchMaury RaycroftMy name is Maury Raycroft, and one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Thomas Schuetz, the CEO of Compass Therapeutics. Thanks so much for joining us today, Thom.Thomas SchuetzThanks, Maury. Thanks for inviting us to the conference. Really appreciate ...

Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The clinical trial approval was granted by the National Medical Products Administration, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its strategic layout for respiratory and skin diseases [1] - The company aims to address the clinical needs of millions of asthma and atopic dermatitis patients globally by continuing to advance innovative therapies for more effective, safer, and more convenient treatment options [1]

QX027N是公司双特异性抗体研发的重要成果，意味着公司在呼吸和皮肤两大疾病领域的协同布局取得 进一步进展。面对全球数亿哮喘与特应性皮炎患者亟待解决的临床需求，公司将持续推进创新疗法的研 发与临床转化，为患者提供更高效、更安全及更便利的治疗选择。 智通财经APP讯，荃信生物-B(02509)发布公告，公司自主研发的长效双抗QX027N注射液获得国家药品 监督管理局药品审评中心的临床试验默示许可(受理号： CXSL2500757，CXSL2500758)，拟用于治疗 哮喘及特应性皮炎。该候选药物的临床许可标志着公司在自免及过敏疾病领域的创新双抗矩阵正式迈入 临床阶段。 ...